| Title |
Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes
|
|---|---|
| Published in |
Diabetes Therapy, July 2017
|
| DOI | 10.1007/s13300-017-0277-0 |
| Pubmed ID | |
| Authors |
Fernando Gomez-Peralta, Cristina Abreu, Albert Lecube, Diego Bellido, Alfonso Soto, Cristóbal Morales, Miguel Brito-Sanfiel, Guillermo Umpierrez |
| Abstract |
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are an attractive novel therapeutic option for the treatment of type 2 diabetes. They block the reabsorption of filtered glucose in kidneys, mainly in proximal renal tubules, resulting in increased urinary glucose excretion and correction of the diabetes-related hyperglycemia. Beyond improving glucose control, SGLT2 inhibitors offer potential benefits by reducing body weight and blood pressure. On the basis of the efficacy demonstrated in clinical trials, SGLT2 inhibitors are recommended as second- or third-line agents for the management of patients with type 2 diabetes. Beneficial effects on kidney disease progression, cardiovascular and all-cause mortality, and hospitalization for heart failure have also been demonstrated with one SGLT2 inhibitor (empagliflozin). Potential adverse events resulting from their mechanism of action or related to concomitant therapies are reviewed. A treatment algorithm for the adjustment of concomitant therapies after initiating SGLT2 inhibitors is also proposed. |
X Demographics
The data shown below were collected from the profiles of 97 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 41 | 42% |
| Mexico | 2 | 2% |
| Venezuela, Bolivarian Republic of | 2 | 2% |
| United States | 1 | 1% |
| Colombia | 1 | 1% |
| Peru | 1 | 1% |
| Portugal | 1 | 1% |
| India | 1 | 1% |
| Saudi Arabia | 1 | 1% |
| Other | 3 | 3% |
| Unknown | 43 | 44% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 71 | 73% |
| Practitioners (doctors, other healthcare professionals) | 20 | 21% |
| Scientists | 3 | 3% |
| Science communicators (journalists, bloggers, editors) | 3 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 136 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 136 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 14 | 10% |
| Researcher | 13 | 10% |
| Student > Master | 13 | 10% |
| Student > Ph. D. Student | 12 | 9% |
| Student > Bachelor | 12 | 9% |
| Other | 27 | 20% |
| Unknown | 45 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 55 | 40% |
| Pharmacology, Toxicology and Pharmaceutical Science | 12 | 9% |
| Biochemistry, Genetics and Molecular Biology | 5 | 4% |
| Nursing and Health Professions | 4 | 3% |
| Agricultural and Biological Sciences | 2 | 1% |
| Other | 9 | 7% |
| Unknown | 49 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 60. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 October 2022.
All research outputs
#721,338
of 25,732,188 outputs
Outputs from Diabetes Therapy
#27
of 1,184 outputs
Outputs of similar age
#14,819
of 326,287 outputs
Outputs of similar age from Diabetes Therapy
#1
of 19 outputs
Altmetric has tracked 25,732,188 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,184 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 326,287 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.